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Abstract
Background: The cattle ticks, Boophilus spp., affect cattle production in tropical and subtropical
regions of the world. Tick vaccines constitute a cost-effective and environmentally friendly
alternative to tick control. The recombinant B. microplus Bm86 protective antigen has been shown
to protect cattle against tick infestations. Recently, the gene coding for B. annulatus Bm86 ortholog,
Ba86, was cloned and the recombinant protein was secreted and purified from the yeast Pichia
pastoris.
Results: Recombinant Ba86 (Israel strain) was used to immunize cattle to test its efficacy for the
control of B. annulatus (Mercedes, Texas, USA strain) and B. microplus (Susceptible, Mexico strain)
infestations. Bm86 (Gavac and Mozambique strain) and adjuvant/saline were used as positive and
negative controls, respectively. Vaccination with Ba86 reduced tick infestations (71% and 40%),
weight (8% and 15%), oviposition (22% and 5%) and egg fertility (25% and 50%) for B. annulatus and
B. microplus, respectively. The efficacy of both Ba86 and Bm86 was higher for B. annulatus than for
B. microplus. The efficacy of Ba86 was higher for B. annulatus (83.0%) than for B. microplus (71.5%).
The efficacy of Bm86 (Gavac; 85.2%) but not Bm86 (Mozambique strain; 70.4%) was higher than
that of Ba86 (71.5%) on B. microplus. However, the efficacy of Bm86 (both Gavac and Mozambique
strain; 99.6%) was higher than that of Ba86 (83.0%) on B. annulatus.
Conclusion: These experiments showed the efficacy of recombinant Ba86 for the control of B.
annulatus and B. microplus infestations in cattle and suggested that physiological differences between
B. microplus and B. annulatus and those encoded in the sequence of Bm86 orthologs may be
responsible for the differences in susceptibility of these tick species to Bm86 vaccines.
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Boophilus spp. (recently considered a synonym of Rhipi-
cephalus (Boophilus) spp.) ticks are distributed in tropical
and subtropical regions of the world with range expansion
for some species due to changes in climatic conditions [1-
3]. Infestations with the cattle tick, Boophilus microplus,
economically impact cattle production by reducing
weight gain and milk production, and by transmitting
pathogens that cause babesiosis (Babesia bovis and B.
bigemina) and anaplasmosis (Anaplasma marginale) [4]. B.
annulatus is present in regions of Asia, Latin America and
Africa [2] where it may also affect cattle production and
vector pathogens.
Acaricide application constitutes a major component of
integrated tick control strategies [5]. However, use of aca-
ricides has had limited efficacy in reducing tick infesta-
tions and is often accompanied by serious drawbacks,
including the selection of acaricide-resistant ticks, envi-
ronmental contamination and contamination of milk
and meat products with drug residues [5]. All of these
issues reinforce the need for alternative approaches to
control tick infestations such as the use of hosts with nat-
ural resistance to ticks, pheromone-impregnated decoys
for attracting and killing ticks, biological control agents
and vaccines [6-8].
In the early 1990s, vaccines were developed that induced
immunological protection of vertebrate hosts against tick
infestations. These vaccines contained the recombinant B.
microplus Bm86 gut antigen [8-12]. Two vaccines using
recombinant Bm86 were subsequently registered in Latin
American countries (Gavac) and Australia (TickGARD)
during 1993–1997 [13]. These vaccines reduce the
number of engorging female ticks, their weight and repro-
ductive capacity. Thus the greatest vaccine effect was the
reduction of larval infestations in subsequent generations.
Vaccine controlled field trials in combination with acari-
cide treatments demonstrated that an integrated approach
resulted in control of tick infestations while reducing the
use of acaricides [12-14]. These trials demonstrated that
control of ticks by vaccination has the advantages of being
cost-effective, reducing environmental contamination
and preventing the selection of drug resistant ticks that
result from repeated acaricide application. In addition,
these vaccines may also prevent or reduce transmission of
pathogens by reducing tick populations and/or affecting
tick vectorial capacity [13-15].
Controlled immunization trials have shown that B. micro-
plus Bm86-containing vaccines also protect against related
tick species, B. annulatus and B. decoloratus [16-18]. How-
ever, B. microplus strain-to-strain variations in the suscep-
tibility to Bm86 vaccination have been reported and the
efficacy of the Bm86 vaccine is higher against B. annulatus
than against B. microplus strains [6,16-18]. These results
suggested that Bm86 sequence and/or tick physiological
differences may influence the efficacy of the vaccine in
Boophilus spp. [18-22].
Recently, the gene coding for B. annulatus Bm86 ortholog,
Ba86, was cloned from an Israeli tick strain and the
recombinant protein was secreted and purified from
Pichia pastoris [23]. The Bm86 and Ba86 proteins showed
over 90% similarity and immune cross-reactivity [23].
However, only cattle vaccination and tick infestation
experiments could evaluate the efficacy of Ba86 against B.
annulatus and B. microplus infestations and address the
question of whether differences in the susceptibility to
Bm86 vaccines between these tick species are due to
sequence polymorphisms, physiological characteristics of
the ticks or both.
In the experiments reported herein cattle were vaccinated
with the recombinant Bm86 and Ba86 antigens and
infested with B. annulatus and B. microplus to (i) evaluate
the efficacy of recombinant Ba86 for the control of B.
annulatus and B. microplus infestations and (ii) to provide
evidence of whether sequence polymorphisms, tick phys-
iological differences or both may account for differences
in the efficacy of Bm86 vaccines against Boophilus spp.
infestations.
Results and Discussion
The vaccination with recombinant Ba86 and Bm86 
protected cattle against B. annulatus and B. microplus 
infestations
This is the first report on the protective capacity of recom-
binant Ba86 for the control of cattle tick infestations. To
evaluate the protective capacity of Ba86 against B. micro-
plus and B. annulatus infestations, cattle were vaccinated
with the recombinant protein and compared to cattle vac-
cinated with two Bm86 preparations and adjuvant/saline
control. The vaccinated animals but not the controls
developed antibodies against recombinant proteins (Fig.
1). The antibody titers were similar for all groups when
measured against Ba86 and Bm86 antigens, thus reflecting
the presence of common antigenic epitopes between both
proteins (ref. [23] and Fig. 2). The antibody titers in cattle
vaccinated with Ba86 and Bm86 (Mozambique strain)
were similar and higher than those in animals vaccinated
with Bm86 (Gavac) (Fig. 1). As in previous experiments
[11,20], except for animals vaccinated with Bm86
(Gavac), antibody titers increased after successive vaccina-
tions and reached a peak two weeks after the third vacci-
nation shot. The differences in the antibody response
elicited by Bm86 (Gavac) and Bm86 (Mozambique
strain) antigens could be attributed to differences in vac-
cine preparations (the Bm86 in Gavac was expressed in P.
pastoris as membrane-bound while the Bm86 of thePage 2 of 8
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and/or to other unknown factors such as cattle physiolog-
ical status that have been demonstrated to affect cattle
antibody response to Bm86 [14]. Additionally, as dis-
cussed bellow, Bm86 polymorphisms between Gavac and
Mozambique strain antigens may affect antigen process-
ing and immune response after vaccination [19].
The vaccination with recombinant Ba86 protected cattle
against B. microplus and B. annulatus infestations (Tables 1
Antibody response in vaccinated cattleFigure 1
Antibody response in vaccinated cattle. Bovine serum antibody titers to recombinant Ba86 (Israeli strain) and Bm86 
(Mozambique strain) antigens were determined by ELISA in cattle vaccinated with Bm86 (Gavac, Cuban Camcord strain), Bm86 
(Mozambique strain), Ba86 (Israeli strain) and adjuvant/saline control. Antibody titers in immunized cattle were expressed as 
the OD450 nm value for the highest serum dilution (1:1000) and compared between vaccinated and control cattle using an 
ANOVA test (*P < 0.05). The time of vaccination shots (arrows) and tick infestation are indicated.
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Bm86 preparations, tick vaccines decreased the number
and weight of adult female ticks, oviposition and egg fer-
tility [9,11,12,14,16,18,20-24]. The efficacy of both Ba86
and Bm86 vaccines was higher for B. annulatus than for B.
microplus (Tables 1 and 2). The efficacy of Ba86 was higher
for B. annulatus (83.0%) than for B. microplus (71.5%)
while the efficacy of Bm86 (Gavac; 85.2%) but not Bm86
(Mozambique strain; 70.4%) was higher than that of
Ba86 (71.5%) on B. microplus. However, the efficacy of
Bm86 vaccines was higher than that of Ba86 for B. annu-
latus and similar to previous reports showing close to
100% efficacy of Bm86 for the control of B. annulatus
infestations [16,18]. The efficacy of Bm86 vaccine prepa-
rations against B. microplus was within the range reported
in previous experiments with other tick strains [12,17-
19,24].
Polymorphisms in Bm86 orhtologs and physiological 
differences between B. annulatus and B. microplus may 
account for differences in the efficacy of Bm86 vaccines
The fact that both Ba86 and Bm86 vaccines had a higher
efficacy for B. annulatus than for B. microplus suggested a
tick species-specific effect that resulted in higher suscepti-
bility of B. annulatus to vaccination. This effect may be
related to tick physiological processes such as feeding and
digestion. For example, a higher amount of blood inges-
tion or a lesser protease activity in the gut of B. annulatus
would result in an increase in the number of antibody-
antigen interactions and vaccine efficacy. A direct correla-
tion between antibody titers and vaccine efficacy has been
demonstrated for Bm86-based vaccines [14,24]. Further
experiments would have to be conducted to address this
important issue by comparing the amount of ingested
blood using artificial feeding systems and protease and
antibody gut concentration in feeding ticks between dif-
ferent Boophilus species and strains.
However, two results suggested that polymorphisms in
Bm86 orthologs may also contribute to differences in vac-
cine efficacy between B. annulatus and B. microplus: (i)
Despite lower antibody titers in vaccinated cattle, vaccine
efficacy on B. microplus was higher for Bm86 (Gavac;
Cuban Camcord strain) than for Bm86 (Mozambique
strain) and (ii) the efficacy of Bm86 vaccines was higher
than that of Ba86 on B. annulatus.
Sequence comparison of recombinant Bm86 and Bm86 antigensFig re 2
Sequence comparison of recombinant Bm86 and Bm86 antigens. The protein sequences of the Bm86 (Cuban Cam-
cord in Gavac), Bm86 (Mozambique), Bm86 (Susceptible, Mexico), Ba86 (Israeli strain) and Ba86 (Mission, TX) strains were 
aligned and the antigenic peptides (≥ 7 residues) predicted using the method of Kolaskar and Tongaonkar [29], with a reported 
accuracy of about 75% http://immunax.dfci.harvard.edu/Tools/antigenic.pl. The predicted antigenic peptides are underlined. The 
antigenic peptide present in Bm86 but absent in Ba86 (Israel strain) is shown in underlined red letters. The antigenic peptides 
absent in the Bm86 (Mozambique strain) sequence are shown in underlined blue letters.
1                                     102
Bm86 (Gavac) ESSICSDFGNEFCRNAECEVVPGAEDDFVCKCPRDNMYFNAAEKQCEYKDTCKTRECSYGRCVESNPSKASCVCEASDDLTLQCKIKNDYAIDCRNRGGTAK
Bm86 (Mozambique) ****************************************************************************************E**T**Q*******
Bm86 (Susceptible Mexico) *********************************************************************G*******************F*T**********
Ba86 (Israel) *******************************************************************************************T**********
Ba86(Mercedes TX) ****************************************************************************************E**T**********
103                                   204
Bm86 (Gavac) LRTDGFIGATCDCGEWGAMNMTTRNCVPTTCLRPDLTCKDLCEKNLLQRDSRCCQGWNTANCSAAPPADSYCSPGSPKGPDGQCINACKTKEAGFVCKHGCR
Bm86 (Mozambique) ********************K*************************P****************----------------------D**RM************
Bm86 (Susceptible Mexico) ********************K***************************************************************K***R*************
Ba86 (Israel) ********************K*************************************SPK***********************K*****************
Ba86(Mercedes TX) *****V*************SK*************************************SPK***********************KD**R*************
205                                   306
Bm86 (Gavac) STGKAYECTCPSGSTVAEDGITCKSISHTVSCTAEQKQTCRPTEDCRVHKGTVLCECPWNQHLVGDTCISDCVDKKCHEEFMDCGVYMNRQSCYCPWKSRKP
Bm86 (Mozambique) **D*************************************L*************************************************************
Bm86 (Susceptible Mexico) **D************************Y*****V**************Q*****************************************************
Ba86 (Israel) **D********R*F************PY*GG**V**********N****A*K**************K**G***EN******T********************
Ba86(Mercedes TX) **D********R*F************PY*GG*************S****T*K**************K**G****N******T********************
307                                   408
Bm86 (Gavac) GPNVNINECLLNEYYYTVSFTPNISFDSDHCKWYEDRVLEAIRTSIGKEVFKVEILNCTQDIKARLIAEKPLSKHVLRKLQACEHPIGEWCMMYPKLLIKKN
Bm86 (Mozambique) *******G*********************************V******************G*****************************************
Bm86 (Susceptible Mexico) ********************************R*****************************************Y***************************
Ba86 (Israel) *******G*****************L***Q*D*****************************************N****************************
Ba86(Mercedes TX) *************************L*****D*****************************************N*******T********************
409                                   510
Bm86 (Gavac) SATEIEEENLCDSLLKDQEAAYKGQNKCVKVDNLFWFQCADGYTTTYEMTRGRLRRSVCKAGVSCNENEQSECADKGQIFVYENGKANCQCPPDTKPGEIGC
Bm86 (Mozambique) ***************RN*********************************************************N****C**********************
Bm86 (Susceptible Mexico) ****************N*****************************************************L***N****C**********************
Ba86 (Israel) ****************N*****************************************************L**TN****C**********************
Ba86(Mercedes TX) ****************N*****************************************************L**TN****C**********************
511                                   609
Bm86 (Gavac) IERTTCNPKEIQECQDKKLECVYKNHKAECECPDDHECYREPAKDSCSEEDNGKCQSSGQRCVIENGKAVCKEKSEATTAATTTTKAKDKDPDPGKSSA
Bm86 (Mozambique) ******************************K*******S************************M***N*******D****S******************
Bm86 (Susceptible Mexico) ******************************K*******S*Q**********************M***********************************
Ba86 (Israel) ******************************K****R**S************************M***N**************A******E*********
Ba86(Mercedes TX) ******************************K****R**S************************M******************A*****N**********Page 4 of 8
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antigen in the Mexican (Susceptible) strain used for infes-
tation was 97% homologous to the sequence in Gavac
Cuban Camcord strain but 93% homologous to the
sequence of the Mozambique strain (Fig. 2). These differ-
ences in the sequence of Bm86 may affect the efficacy of
Bm86 vaccines in different strains [19]. For example, two
of the predicted antigenic peptides in Bm86 (Gavac) were
located on a deletion in the Bm86 (Mozambique strain)
sequence but conserved in the Bm86 (Susceptible, Mex-
ico) strain sequence (Fig. 2). The efficacy of the Ba86 vac-
cine on B. microplus, which was slightly higher (71.5%;
Table 1) than that of the Bm86 (Mozambique strain) vac-
cine (70.4%; Table 1) also supports this hypothesis
because the homology to the Bm86 sequence in the Mex-
ican strain used for infestation was also higher for Ba86
(94%) than for Bm86 (Mozambique strain; 93%). How-
ever, as discussed above, differences in the production of
Gavac and the Mozambique strain vaccines [23] together
with cattle physiological factors [14] and antibody isotype
composition [25] may also account for differences in vac-
cine efficacy.
Table 1: Control of B. microplus infestations in cattle vaccinated with the recombinant Ba86 and Bm86 preparations.
Boophilus microplus (Susceptible; Mexico strain)
Percent reduction (vaccinated/control)b Ec
Experimental groupa DT DW DO DF
Ba86 (Israeli strain) 40%
(506 ± 96)*
15%
(252 ± 14)*
5%
(104 ± 11)
50%
(0.2 ± 0.04)*
71.5%
Bm86 (Gavac; Cuban Camcord strain) 59%
(348 ± 99)*
15%
(253 ± 9)*
28%
(78 ± 8)*
50%
(0.2 ± 0.03)*
85.2%
Bm86 (Mozambique strain) 22%
(655 ± 172*)
17%
(245 ± 14)*
24%
(83 ± 11)*
50%
(0.2 ± 0.04)*
70.4%
Adjuvant/saline control 841 ± 94 297 ± 19 109 ± 10 0.4 ± 0.0 ---
aCattle were randomly assigned to experimental groups (N = 5), vaccinated and challenged with B. microplus and B. annulatus larvae.
bThe percent reduction was calculated with respect to the control group: DT, % reduction in tick infestation; DW, % reduction in tick weight; DO, 
% reduction in oviposition; DF, % reduction in egg fertility. In parenthesis are shown the average ± S.E. for adult female tick number, tick weight, 
oviposition and egg fertility and were compared by Student's t-test with unequal variance between vaccinated and control groups. (*P < 0.05).
cVaccine efficacy (E) was calculated as 100 [l-(CRT × CR0 × CRF)], where CRT, CRO and CRF are the reduction in the number of adult female 
ticks, oviposition and egg fertility as compared to the control group, respectively.
Table 2: Control of B. annulatus infestations in cattle vaccinated with the recombinant Ba86 and Bm86 preparations.
Boophilus annulatus (Mission, TX strain)
Percent reduction (vaccinated/control)b Ec
Experimental groupa DT DW DO DF
Ba86 (Israeli strain) 71%
(217 ± 128)*
8%
(285 ± 17)
22%
(89 ± 10)*
25%
(0.3 ± 0.1)*
83.0%
Bm86 (Gavac; Cuban Camcord strain) 95%
(34 ± 33)*
54%
(141 ± 59)*
66%
(39 ± 17)*
75%
(0.1 ± 0.1)*
99.6%
Bm86 (Mozambique strain) 99%
(4 ± 2)*
23%
(240 ± 62)
25%
(85 ± 24)*
50%
(0.2 ± 0.1)*
99.6%
Adjuvant/saline control 750 ± 127 310 ± 52 114 ± 8 0.4 ± 0.04 ---
aCattle were randomly assigned to experimental groups (N = 5), vaccinated and challenged with B. microplus and B. annulatus larvae.
bThe percent reduction was calculated with respect to the control group: DT, % reduction in tick infestation; DW, % reduction in tick weight; DO, 
% reduction in oviposition; DF, % reduction in egg fertility. In parenthesis are shown the average ± S.E. for adult female tick number, tick weight, 
oviposition and egg fertility and were compared by Student's t-test with unequal variance between vaccinated and control groups. (*P < 0.05).
cVaccine efficacy (E) was calculated as 100 [l-(CRT × CR0 × CRF)], where CRT, CRO and CRF are the reduction in the number of adult female 
ticks, oviposition and egg fertility as compared to the control group, respectively.Page 5 of 8
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latus to vaccination discussed above, the analysis of pre-
dicted antigenic regions in Ba86 and Bm86 also suggested
an effect of protein sequence on vaccine efficacy. Several
predicted antigenic regions were polymorphic between
Bm86 and Ba86 (Fig. 2). Furthermore, Bm86 contained
one predicted antigenic region not present in Ba86 (Israel
strain) but present in Ba86 (Mercedes, Texas strain) (Fig.
2). The predicted antigenic regions may contain protective
epitopes and thus could be involved in eliciting a protec-
tive response after vaccination. Therefore, polymorphisms
in these regions could explain, at least for some Ba86 anti-
gens, the higher efficacy of Bm86 vaccines for the control
of B. annulatus.
Conclusion
The results reported herein demonstrated the efficacy of
recombinant Ba86 for the control of B. annulatus and B.
microplus infestations in cattle. These experiments also
expanded the results of the efficacy of Bm86 vaccines by
including protection against cattle infestation by new
strains of B. anulatus (Mercedes, Texas, USA) and B. micro-
plus (Susceptible, Mexico). Finally, these results suggested
that physiological differences between B. microplus and B.
annulatus and those encoded in the sequence of Bm86
orthologs may be responsible for the differences in sus-
ceptibility of these tick species to Bm86 vaccines.
Methods
Tick strains
The B. microplus (Susceptible, CENAPA, Mexico strain)
and B. annulatus (Mercedes, Texas, USA strain) ticks were
obtained from laboratory colonies maintained at the Uni-
versity of Tamaulipas, Mexico. Originally, these tick
strains were collected from infested cattle in Tapalpa,
Jalisco, Mexico and Mercedes County, Texas, USA for B.
microplus and B. annulatus, respectively. Ticks were main-
tained during two years at the facilities of the Faculty of
Veterinary Medicine, University of Tamaulipas, where sev-
eral generations of tick larvae were fed on cows and col-
lected until repletion to allow for oviposition and
hatching in humidity chambers at 12 hr light: 12 hr dark
photoperiod, 22–25°C and 95% relative humidity. Lar-
vae were 15 days of age at the time of infestations.
Vaccine formulations
The recombinant Ba86 (Israeli strain) and Bm86
(Mozambique strain) were secreted in P. pastoris and puri-
fied as reported previously [23]. Protein adjuvation was
made by mixing a solution of anhydromannitoletherocto-
decenoate (Montanide ISA 50 V; Seppic, Paris, France)
with the recombinant protein solution in batch-by-batch
processes using a high-speed mixer Heidolph DIAX 900
(Heidolph Elektro, Kelheim, Germany) at 8,000 rpm and
the vaccine was filled manually under sterile conditions in
glass bottles of 20 ml (Wheaton, Millville, NJ, USA) at a
concentration of 100 μg/2 ml dose. Quality controls were
made by testing mechanical and thermal stability of vac-
cine emulsions as described by Canales et al. [26]. The
commercial Bm86 (Cuban Camcord strain) vaccine
(Gavac, Revetmex, Mexico City, Mexico) also contains
100 μg/2 ml dose of P. pastoris-derived purified recom-
binant protein formulated as described above.
Cattle immunization with recombinant proteins and tick 
infestations
Five crossbred calves per group were each immunized
with 3 doses (weeks 1, 3 and 7) containing 100 μg/dose
of purified recombinant proteins formulated as described
above. Negative controls were injected with adjuvant/
saline alone. Cattle were injected intramuscularly with 2
ml/dose using a 5 ml syringe and an 18G needle. Twelve
days after the last immunization, cattle in vaccinated and
control groups were infested with 10,000 B. annulatus
(Mercedes, Texas, USA strain) and B. microplus (Suscepti-
ble, Mexico strain) larvae/animal applied individually to
each animal in separate cotton cells attached to the back
of the animals. Cattle were cared for in accordance with
standards specified in the Guide for Care and Use of Lab-
oratory Animals.
Data collection and evaluation
Adult female ticks dropping from cattle were daily col-
lected, counted and weighted. All the collected adult
female ticks were assessed for oviposition and egg fertility
[27]. The personnel collecting the ticks were 'blinded' as
to which group animals belonged. The efficacy of vaccine
formulations was evaluated employing the following for-
mulae [27].
Effect on the number of adult female ticks (DT) = 100 [l-
(NTV/NTC)], where NTV is the number of adult female
ticks in the vaccinated group and NTC is the number of
adult female ticks in the control group.
Effect on tick weight (DW) = 100 [1-(WTV/WTC)], where
WTV is the average adult female tick weight in the vacci-
nated group and WTC is the average adult female tick
weight in the control group.
Effect on oviposition (DO) = 100 [1-(PATV/PATC)],
where PATV is the average weight of the eggs per survived
tick in the vaccinated group and PATC is the average
weight of the eggs per survived tick in the control group.
Effect on egg fertility (DF) = 100 [1-(PPLOV/PPLOC)],
where PPLOV is the average weight of the larvae per gram
of eggs in the vaccinated group and PPLOC is the average
weight of the larvae per gram of eggs in the control group.Page 6 of 8
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CRF)], where CRT = NTV/NTC, CR0 = PATV/PATC and
CRF = PPLOV/PPLOC that represent the reduction in the
number of adult female ticks, oviposition and egg fertility
as compared to the control group, respectively.
A Student's t-test with unequal variance (P = 0.05) was
used to compare the results of adult female tick number,
tick weight, oviposition and egg fertility between vacci-
nated and control groups.
Determination of serum antibody levels by ELISA
Before each immunization and 12 (before tick infesta-
tion) and 37 days after the last immunization, blood sam-
ples were collected from each calf into sterile tubes and
maintained at 4°C until arrival at the laboratory. Serum
was then separated after centrifugation and stored at -
20°C. Serum antibody titers were determined using an
antigen-specific indirect ELISA. Purified recombinant
Bm86 (Mozambique strain) and Ba86 (Israeli strain) anti-
gens (0.1 μg/well) were used to coat ELISA plates over-
night at 4°C. Sera were serially diluted to 1:10, 1:100 and
1:1000 in PBST (PBS/0.5% Tween 20, pH 7.2) and 10%
fetal bovine serum (Sigma). The plates were incubated
with the diluted sera for 1 hr at 37°C and then incubated
with 1:10,000 rabbit anti-bovine IgG-HRP conjugates
(Sigma) for 1 hr at 37°C. The color reaction was devel-
oped with 3,3',5,5'-tetramethylbenzidine (Sigma) and the
OD450 nm was determined. After incubation the plates
were washed with PBST. Antibody titers were considered
positive when they yielded an OD450 nm value at least
twice as high as the preimmune serum. Antibody titers in
immunized cattle were expressed as the OD450 nm value for
the highest serum dilution (1:1000) and compared
between vaccinated and control cattle using an ANOVA
test (P < 0.05).
Sequence analysis
The sequences of the Ba86 (Mercedes, Texas, USA; Gen-
bank accession number FJ456927) and Bm86 (Suscepti-
ble, Mexico; FJ456928) strains were determined as
described previously [23]. The protein sequences were
aligned with Ba86 (Israeli strain; ABY58969), Bm86
(Mozambique strain; ABY58968) and Bm86 (Cuban
Camcord strain in Gavac; [11]) using the program AlignX
(Vector NTI Suite V 8.0, InforMax, Invitrogen, Carlsbad,
CA, USA) with an engine based on the Clustal W algo-
rithm [28]. Antigenic peptides (=7 residues) were pre-
dicted using the method of Kolaskar and Tongaonkar
[29], with a reported accuracy of about 75% http://immu
nax.dfci.harvard.edu/Tools/antigenic.pl.
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